1. Home
  2. INMB vs ACET Comparison

INMB vs ACET Comparison

Compare INMB & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo INmune Bio Inc.

INMB

INmune Bio Inc.

HOLD

Current Price

$1.41

Market Cap

37.2M

Sector

Health Care

ML Signal

HOLD

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

HOLD

Current Price

$9.09

Market Cap

77.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INMB
ACET
Founded
2015
1947
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
37.2M
77.3M
IPO Year
2018
2017

Fundamental Metrics

Financial Performance
Metric
INMB
ACET
Price
$1.41
$9.09
Analyst Decision
Buy
Strong Buy
Analyst Count
5
3
Target Price
$5.40
$48.33
AVG Volume (30 Days)
421.4K
92.0K
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
11.85
N/A
EPS
N/A
N/A
Revenue
$50,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
257.14
N/A
52 Week Low
$1.09
$0.46
52 Week High
$11.64
$9.05

Technical Indicators

Market Signals
Indicator
INMB
ACET
Relative Strength Index (RSI) 48.57 65.02
Support Level $1.37 $7.36
Resistance Level $1.51 N/A
Average True Range (ATR) 0.11 0.56
MACD -0.01 0.08
Stochastic Oscillator 20.83 97.60

Price Performance

Historical Comparison
INMB
ACET

About INMB INmune Bio Inc.

INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).

Share on Social Networks: